Intrabio Inc

Intrabio Inc company information, Employees & Contact Information

Explore related pages

Related company profiles:

IntraBio Inc is a pharmaceutical company located in Austin, Texas focusing on drug discovery, development, and commercialization related to rare and common neurodegenerative and neurodevelopmental diseases.

Company Details

Employees
28
Address
201 W 5th St,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Austin, Texas
Looking for a particular Intrabio Inc employee's phone or email?

Intrabio Inc Questions

News

Pharma start-up IntraBio and CEO Mallory Factor patently mean business - IAM Patent

Pharma start-up IntraBio and CEO Mallory Factor patently mean business IAM Patent

IntraBio Inc. Completes Recruitment for IB1001 A-T Pivotal Clinical Trial - BioSpace

IntraBio Inc. Completes Recruitment for IB1001 A-T Pivotal Clinical Trial BioSpace

AQNEURSA® (levacetylleucine) Recommended for EU Approval by the CHMP to Treat Niemann-Pick Disease Type C - BioSpace

AQNEURSA® (levacetylleucine) Recommended for EU Approval by the CHMP to Treat Niemann-Pick Disease Type C BioSpace

N-Acetyl-L-Leucine Reduces Disease Progression in Phase 2 Extension Study for Ataxia-Telangiectasia - NeurologyLive

N-Acetyl-L-Leucine Reduces Disease Progression in Phase 2 Extension Study for Ataxia-Telangiectasia NeurologyLive

IntraBio Announces U.S. FDA Accepts New Drug Application for IB1001 for the Treatment of Niemann-Pick Disease Type C - Yahoo Finance

IntraBio Announces U.S. FDA Accepts New Drug Application for IB1001 for the Treatment of Niemann-Pick Disease Type C Yahoo Finance

How IntraBio's finance transformation fueled its global expansion - EY

How IntraBio's finance transformation fueled its global expansion EY

IntraBio Announces U.S. FDA Approval of AQNEURSA for the Treatment of Niemann-Pick Disease Type C - Business Wire

IntraBio Announces U.S. FDA Approval of AQNEURSA for the Treatment of Niemann-Pick Disease Type C Business Wire

FDA Approves Levacetylleucine for Niemann-Pick Disease Type C - HCPLive

FDA Approves Levacetylleucine for Niemann-Pick Disease Type C HCPLive

US FDA approves IntraBio's drug for rare genetic disease - Reuters

US FDA approves IntraBio's drug for rare genetic disease Reuters

Austin's IntraBio accelerates hope for rare neurological disease treatment - KEYE

Austin's IntraBio accelerates hope for rare neurological disease treatment KEYE

IntraBio muscles in on Zevra's turf after companies' back-to-back lysosomal storage disorder nods - Fierce Pharma

IntraBio muscles in on Zevra's turf after companies' back-to-back lysosomal storage disorder nods Fierce Pharma

IntraBio Update - Yahoo Finance

IntraBio Update Yahoo Finance

After landmark rare disease approval, IntraBio ready to 'hit the ground running' with Aqneursa launch - Fierce Pharma

After landmark rare disease approval, IntraBio ready to 'hit the ground running' with Aqneursa launch Fierce Pharma

FDA Approves Stand-Alone Therapy Levacetylleucine for Niemann-Pick Disease Type C - NeurologyLive

FDA Approves Stand-Alone Therapy Levacetylleucine for Niemann-Pick Disease Type C NeurologyLive

Curant Health Selected By IntraBio as the Exclusive Specialty Pharmacy for AQNEURSA - Business Wire

Curant Health Selected By IntraBio as the Exclusive Specialty Pharmacy for AQNEURSA Business Wire

IntraBio Wins FDA Nod for Ultra-Rare Neurodegenerative Disease on Heels of Competitor’s Approval - BioSpace

IntraBio Wins FDA Nod for Ultra-Rare Neurodegenerative Disease on Heels of Competitor’s Approval BioSpace

Fractus IoT enforcement; Ericsson Q3 results; IntraBio CEO interview; Samsung ETSI complaint order; UK SEP proposal kickback; plus much more - IAM Patent

Fractus IoT enforcement; Ericsson Q3 results; IntraBio CEO interview; Samsung ETSI complaint order; UK SEP proposal kickback; plus much more IAM Patent

Take your (Niemann-) Pick: Intrabio’s Aqneursa wins FDA nod - BioWorld MedTech

Take your (Niemann-) Pick: Intrabio’s Aqneursa wins FDA nod BioWorld MedTech

Quince Therapeutics Updates on IntraBio Phase 2 Study - TradingView

Quince Therapeutics Updates on IntraBio Phase 2 Study TradingView

UK biopharma company IntraBio moves HQ to Austin, raises $40M - The Business Journals

UK biopharma company IntraBio moves HQ to Austin, raises $40M The Business Journals

Acetylation turns leucine into a drug by membrane transporter switching - Nature

Acetylation turns leucine into a drug by membrane transporter switching Nature

FDA Approves First Treatments for Niemann-Pick Disease Type C - NAVLIN DAILY

FDA Approves First Treatments for Niemann-Pick Disease Type C NAVLIN DAILY

FDA Approves Levacetylleucine for Treatment of Niemann-Pick Disease Type C - Drug Topics

FDA Approves Levacetylleucine for Treatment of Niemann-Pick Disease Type C Drug Topics

EY Unveils Finance Service Built on SAP Cloud Technology - FinTech Magazine

EY Unveils Finance Service Built on SAP Cloud Technology FinTech Magazine

N-acetyl-L-leucine improves symptoms and functioning in GM2 Gangliosidosis (Tay-Sachs & Sandhoff) - medRxiv

N-acetyl-L-leucine improves symptoms and functioning in GM2 Gangliosidosis (Tay-Sachs & Sandhoff) medRxiv

IntraBio Receives Niemann-Pick Disease European Orphan Drug Designation - drugdiscoverytrends.com

IntraBio Receives Niemann-Pick Disease European Orphan Drug Designation drugdiscoverytrends.com

Top Intrabio Inc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant